JPRN-UMIN000006518招募中2 期
Phase II study of erlotinib in advanced or recurrent EGFR mutation positive Non-small cell lung cancer patients who were previously treated with intrapleural therapy for malignant pleural effusion. - Phase II study of erlotinib in advanced or recurrent EGFR mutation positive NSCLC patients who were previously treated with intrapleural therapy for malignant pleural effusion.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1,Massive pericardial effusion or ascites 2,Severe drug allergy 3,Active infection 4,Continuous watery diarrhea 5,Intestinal paralysis or ileus 6,Interstitial pneumonia or lung fibrosis evident on CT 7,Symptomatic ophthalmologic disease 8,Current or previous (within the last 1 year) history of GI perforation 9,Serious non—healing ulcer 10,Symptomatic or steroid-requiring brain metastases 11,Active concomitant malignancy 12,Previous (within the last 5 years) concomitant malignancy 13,Uncontrolled diabetes 14,Severe cardiac disease 15,Severe psychological disease 16,Pregnant or lactating women or those who declined contraception 17,Those judged to be not suitable by the attending physician
研究者
相似试验
已完成
不适用
PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFRPre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000005491Hiroshima citizens hospital Department of Medical Oncology40
已完成
2 期
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild typeadvanced or recurrent non-small-cell lung cancerJPRN-UMIN000008398Gunma Uninersity Hospital30
已完成
2 期
Phase II study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR(NEJ006/TCOG0903)Pre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000002795orth East Japan Study Group /The Tokyo Cooperative Oncology Group43
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54